| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED AUGUST 2016. Refer to TA404: Degarelix for treating advanced hormone-dependent prostate cancer for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | degarelix (Firmagon®) | ||
| Formulation | 80 mg powder and solvent for solution for injection, 120 mg powder and solvent for solution for injection | ||
| Reference number | 755 | ||
| Indication | Treatment of adult male patients with advanced hormone-dependent prostate cancer |
||
| Company | Ferring Pharmaceuticals (UK) | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Resubmission | ||
| Status | Superseded | ||
| Advice number | 4112 | ||
| NMG meeting date | 09/10/2012 | ||
| AWMSG meeting date | 14/11/2012 | ||
| Ratification by Welsh Government | 11/12/2012 | ||
| Date of issue | 13/12/2012 | ||
| Date of last review | 30/08/2016 | ||
| NICE guidance | TA404: Degarelix for treating advanced hormone-dependent prostate cancer (external website - opens in new window) |
||
| Commercial arrangement | WPAS | ||